Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer and pancreatic cancer. It works by blocking the EGFR, which is involved in cancer cell growth. Rosuvastatin is a statin that inhibits HMG-CoA reductase, an enzyme crucial for cholesterol synthesis. It is used to lower cholesterol levels and reduce the risk of cardiovascular diseases. The combination of erlotinib and rosuvastatin has been explored in clinical trials for synergistic effects in cancer treatment, though it is not a standard combination for cancer therapy.
- Brand names
- Tarceva (erlotinib)Crestor (rosuvastatin)Ezallor Sprinkle (rosuvastatin)
02
Targets
EGFR (Epidermal growth factor receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on erlotinib + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + rosuvastatin.